| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
EV-ICD defibrillation lead placed outside of heart and veins, preserving vasculature DUBLIN, Feb. 17, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) has received CE (Conformité Européenne) Mark...
ISC23: Late-breaking results from STROKE AF study reinforce importance of long-term continuous cardiac monitoring in ischemic stroke patients DUBLIN and DALLAS, Feb. 8, 2023 /PRNewswire/ --...
SPHERE Per-AF will determine the safety and effectiveness of the Sphere-9 cardiac ablation and mapping catheter with the Affera mapping and navigation system DUBLIN, Dec. 5, 2022 /PRNewswire/ --...
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The data were presented...
Medtronic "Conduction System Pacing" Expanded Indication Now Includes Left Bundle Branch Area Pacing in Addition to His-Bundle Pacing for Patients with Slow Heart Rates DUBLIN, Oct. 17, 2022...
The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global...
Long-term analysis from landmark renal denervation trial presented as Late Breaking Clinical Science, published simultaneously in The Lancet Data add to growing body of evidence supporting the...
Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias
Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success DUBLIN and BARCELONA,
Partnership underscores Medtronic's commitment to investing in innovative technologies that support physicians and patients from diagnosis to treatment CathWorks' FFRangio® System provides...
Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE DUBLIN and PARIS, May 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT),...
The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent DUBLIN, May 13, 2022 /
Medtronic adds to its robust clinical program with long-term data demonstrating the continued blood pressure lowering effect of the Symplicity renal denervation procedure Medtronic also completes...
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the Freezor™ and Freezor™ Xtra Cardiac Cryoablation Catheters are approved by the U.S. Food and Drug...
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received approval from Japan's Ministry of Health, Labor and Welfare for the sale and reimbursement of...
First Medtronic TAVR system approved in China for patients with symptomatic severe aortic stenosis DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare...
Acquisition to expand company's cardiac ablation portfolio, including first-time entry into mapping and navigation, within one of the fastest growing medtech markets DUBLIN, Jan. 10, 2022...
Transfemoral access added into landmark APOLLO Pivotal Trial following IDE approval from FDA DUBLIN and ORLANDO, Fla., Nov. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...
TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years DUBLIN and ORLANDO, Fla., Nov. 5, 2021 /PRNewswire/ -- Medtronic plc...
New data from Medtronic Patient Preference study presented at TCT 2021; Medtronic adds to its clinical leadership for renal denervation with launch of the SPYRAL AFFIRM study DUBLIN and ORLANDO,...
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the publication of a study demonstrating, through the use of a Medtronic continuous rhythm monitoring device,...
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced a pilot program with Mpirik to address disparities in care associated with the prevention of sudden cardiac...
Results Presented at ESC 2021 Show Micra TPS Compares Favorably to Traditional Pacemakers DUBLIN, Aug. 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology,...
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic...
AI Algorithms Enhance LINQ II™ Insertable Cardiac Monitor Diagnostic Accuracy for Improved Management of Patients DUBLIN, July 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global...